Delaware is currently home to 288 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Newark, Wilmington, Lewes and Rehoboth Beach. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Recruiting
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/19/2024
Locations: Research Site, Wilmington, Delaware
Conditions: Asthma
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Recruiting
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Medical Oncology Hematology Consultants, Newark, Delaware
Conditions: Multiple Myeloma
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
MALE
Ages:
All
Trial Updated:
12/18/2024
Locations: Home-based telemedicine, Dover, Delaware
Conditions: Chronic Granulomatous Disease (CGD)
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Recruiting
This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
12/18/2024
Locations: Research Site, Newark, Delaware
Conditions: Breast Cancer
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
Recruiting
To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Site Number - 1547, Newark, Delaware
Conditions: Thyroid Eye Disease
Osteogenesis Imperfecta Blood Pressure Study
Recruiting
Osteogenesis Imperfecta (OI) is a genetic disorder caused by mutations to the alpha-1 or alpha-2 chain of type I collagen. Clinically, the disorder is characterized by bones that fracture easily, often from little or no apparent trauma. There is no information about Some institutions perform blood pressure monitoring on these patients with a cuff, while other institutions avoid this method due to concern for fracture. Instead, they use alternative forms of monitoring such as an arterial line. Th... Read More
Gender:
ALL
Ages:
Between 1 year and 35 years
Trial Updated:
12/18/2024
Locations: Nemours / A I duPont Hospital for Children, Wilmington, Delaware
Conditions: Osteogenesis Imperfecta
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
Recruiting
The purpose of this study is to identify the impact of estradiol (E2) on the associations between (a) responsivity to daily stress or (b) sleep variability with vascular function in midlife premenopausal women.
Gender:
FEMALE
Ages:
Between 40 years and 55 years
Trial Updated:
12/17/2024
Locations: University of Delaware, Newark, Delaware
Conditions: Estrogen, Premenopause
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Recruiting
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Research Site, Newark, Delaware
Conditions: Breast Cancer
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
Recruiting
The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Gender:
ALL
Ages:
30 years and below
Trial Updated:
12/16/2024
Locations: Local Institution - 0061, Wilmington, Delaware
Conditions: Lymphoma, Non-Hodgkin, Hodgkin Disease
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Research Site, Newark, Delaware
Conditions: Non-small Cell Lung Cancer
HEARTPrep: a Virtually-delivered Psychosocial Intervention for Mothers Expecting a Baby with Congenital Heart Disease
Recruiting
Congenital heart disease (CHD) is the most common birth defect and is increasingly diagnosed prenatally. Mothers describe their prenatal experiences as highly stressful and traumatic after a diagnosis of CHD. Maternal stress during pregnancy exerts a powerful influence on birth outcomes and developmental trajectories, particularly for children in underserved populations. In partnership with diverse parent and clinician stakeholders, our team designed HEARTPrep, an innovative, virtually-delivered... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Nemours Children's Health, Wilmington, Delaware
Conditions: Congenital Heart Disease
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab Vs Pembrolizumab in First-line Treatment of Head and Neck Cancer
Recruiting
This is Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2024
Locations: Site 19, Newark, Delaware
Conditions: Head and Neck Squamous Cell Carcinoma